SCHEMBL15879367

SCHEMBL15879367

CC(C)(C)C(=O)Nc1cc(CCBr)c(CC(=O)O)cn1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 6/20 0.44
CNR1 P21554 3/20 0.38
ABL1 P00519 1/20 0.35
ADORA1 P30542 2/20 0.35
NPC1 O15118 3/20 0.34
RAB9A P51151 3/20 0.34
KDR P35968 2/20 0.34
GRIN2B Q13224 1/20 0.33
MAPT P10636 1/20 0.33
GSK3B P49841 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
MAPK1 P28482 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
ALDH1A1 P00352 1/20 0.32
TP53 P04637 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15879718 0.88 CNR2 (0.45) CNR2CNR1ABL1ADORA1NPC1
SCHEMBL15191862 0.79 CNR2 (0.42) CNR2CNR1ABL1ADORA1NPC1
SCHEMBL30207752 0.78 CNR2 (0.49) CNR2CNR1ABL1ADORA1NPC1
SCHEMBL2730896 0.72 CNR2 (0.49) CNR2CNR1ABL1ADORA1NPC1
SCHEMBL8329180 0.71 CNR2 (0.53) CNR2CNR1ABL1ADORA1NPC1
SCHEMBL16862351 0.69 CNR2 (0.36) CNR2ABL1ADORA1NPC1RAB9A
SCHEMBL8325829 0.68 CNR2 (0.47) CNR2CNR1ABL1NPC1RAB9A
SCHEMBL10172952 0.68 CNR2 (0.53) CNR2CNR1ABL1ADORA1NPC1
SCHEMBL2733632 0.68 CNR2 (0.42) CNR2CNR1ABL1ADORA1NPC1
SCHEMBL3297481 0.67 CNR2 (0.38) CNR2ABL1ADORA1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9839629-B2 Inhibitors of the renal outer medullary potassium channel MERCK SHARP & DOHME CORP. (US) 2017-12-12 US disclosed
US-20160324833-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME LLC 2016-11-10 US disclosed
US-9062070-B2 Inhibitors of the renal outer medullary potassium channel MERCK SHARP & DOHME CORP. (US) 2015-06-23 US disclosed
US-20140206618-A1 Inhibitors of the Renal Outer Medullary Potassium Channel MERCK SHARP & DOHME LLC 2014-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160324833-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL KCNJ11, WNK1, KCNJ1 CNR2 3553/4885CNR1 2593/4885ABL1 2920/4885
US-20140206618-A1 Inhibitors of the Renal Outer Medullary Potassium Channel KCNJ11, KCNJ1, KCNJ2 CNR2 3950/4885CNR1 3291/4885ABL1 2191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.